BACKGROUND/AIMS: Some sodium glucose co-transporter 2 (SGLT2) inhibitors are 
approved for the treatment of patients with type 2 diabetes mellitus (T2DM) with 
an estimated glomerular filtration rate (eGFR) of ≥45 ml/min/1.73 m(2). The 
efficacy and safety of canagliflozin, an approved SGLT2 inhibitor, was evaluated 
in patients with stage 3 chronic kidney disease (CKD; eGFR ≥30 to <60 
ml/min/1.73 m(2)).
METHODS: This analysis used integrated data from four randomized, 
placebo-controlled, phase 3 studies that enrolled patients with T2DM and stage 3 
CKD. RESULTS are presented for the overall population as well as subgroups with 
stage 3a CKD (eGFR ≥45 and <60 ml/min/1.73 m(2)) and stage 3b CKD (eGFR ≥30 and 
<45 ml/min/1.73 m(2)).
RESULTS: Among all subjects studied with stage 3 CKD, placebo-subtracted 
reductions in HbA1c (-0.38 and -0.47%; p < 0.001), body weight (-1.6 and -1.9%; 
p < 0.001), and systolic blood pressure (-2.8 and -4.4 mm Hg; p < 0.01) were 
seen with canagliflozin 100 and 300 mg, respectively. Decreases in HbA1c, body 
weight, and systolic blood pressure were examined in the stage 3a and 3b CKD 
subgroups, with greater decreases in HbA1c, -0.47% (-0.61, -0.32) and body 
weight in subjects in stage 3a CKD, -1.8% (-2.3, -1.2) with canagliflozin 100 
mg. Initial declines in eGFR were seen early following treatment initiation with 
canagliflozin, but trended towards baseline over time. The most common adverse 
events with canagliflozin included genital mycotic infections and adverse events 
related to reduced intravascular volume likely secondary to osmotic diuresis.
CONCLUSION: In subjects with T2DM and stage 3 CKD, canagliflozin reduced HbA1c, 
body weight, and blood pressure, and was generally well tolerated.